Drug Profile
MPI 676
Alternative Names: MPI-676Latest Information Update: 24 Dec 2021
Price :
$50
*
At a glance
- Originator Mount Sinai Hospital (Toronto); Wayne State University
- Developer Meditrina Pharmaceuticals
- Class Antineoplastics; Nitriles; Small molecules; Triazoles
- Mechanism of Action Aromatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Endometriosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Endometriosis in USA (PO)
- 17 Jul 2008 Preclinical trials in Endometriosis in USA (PO)